Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

11 févr. 2016 11h30 HE | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Favorable Judgment by the District Court of Massachusetts

CANTON, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the District Court of Massachusetts issued an order for final judgment in favor of...
04 févr. 2016 08h18 HE | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Issuance of U.S. Patent Covering DETERx®, an Abuse-Deterrent, Extended-Release Technology Platform

CANTON, Mass., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that U.S. Patent No. 9,248,195 entitled, "Abuse-deterrent Pharmaceutical Compositions...
02 févr. 2016 08h45 HE | Source: Collegium Pharmaceutical, Inc.

Collegium Provides Litigation Update

CANTON, Mass., Feb. 02, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today provided an update regarding its ongoing litigation with Purdue Pharma L.P. (“Purdue”). On...
25 janv. 2016 07h00 HE | Source: Collegium Pharmaceutical, Inc.

Collegium Appoints Ted Schroeder to Board of Directors

CANTON, Mass., Jan. 25, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the appointment of Ted Schroeder to its board of directors. Mr. Schroeder led...
21 janv. 2016 09h00 HE | Source: Collegium Pharmaceutical, Inc.

Collegium Announces FDA Acceptance of IND Application for Abuse-Deterrent, Hydrocodone DETERx®

CANTON, Mass., Jan. 21, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s...
08 janv. 2016 06h00 HE | Source: Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. Prices Public Offering of $55.0 Million of Common Stock

CANTON, Mass., Jan. 08, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the pricing of its public offering of 2,750,000 shares of its common stock at a price...
16 déc. 2015 09h00 HE | Source: Collegium Pharmaceutical, Inc.

Collegium Announces Publication of Nasal Human Abuse Potential Study in American Academy of Pain Medicine

CANTON, Mass., Dec. 16, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of results from the intranasal human abuse potential of Xtampza™ ER...
14 déc. 2015 17h00 HE | Source: Collegium Pharmaceutical, Inc.

Collegium Added to the NASDAQ Biotechnology Index

CANTON, Mass., Dec. 14, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today that it has been selected for addition to the NASDAQ Biotechnology Index (Nasdaq:NBI)....
17 mars 2015 07h00 HE | Source: Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical to Present Xtampza ER(TM) Pivotal Phase III Data at the 2015 American Academy of Pain Medicine Annual Meeting

CANTON, Mass., March 17, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. today announced a poster presentation of the Company's completed Phase III clinical trial that evaluated the efficacy...
10 mars 2015 07h00 HE | Source: Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical Raises $50 Million Financing to Support Commercial Development of Its Lead Abuse-Deterrent Product Candidate

CANTON, Mass., March 10, 2015 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative abuse-deterrent...

Page précédente